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ABSTRACT: As a key player of the protein quality control
network of the cell, the molecular chaperone Hsp70 inhibits
the aggregation of the amyloid protein tau. To date, the
mechanism of this inhibition and the tau species targeted by
Hsp70 remain unknown. This is partly due to the inherent
difficulty of studying amyloid aggregates because of their
heterogeneous and transient nature. Here, we used ensemble
and single-molecule fluorescence measurements to dissect how
Hsp70 counteracts the self-assembly process of the K18
ΔK280 tau variant. We found that Hsp70 blocks the early
stages of tau aggregation by suppressing the formation of tau
nuclei. Additionally, Hsp70 sequesters oligomers and mature
tau fibrils with nanomolar affinity into a protective complex, efficiently neutralizing their ability to damage membranes and seed
further tau aggregation. Our results provide novel insights into the molecular mechanisms by which the chaperone Hsp70
counteracts the formation, propagation, and toxicity of tau aggregates.
T he aberrant aggregation of tau into intracellular deposits isthought to play a key role in the pathogenesis of various
human tauopathies including Alzheimer’s disease (AD).1
During disease, tau forms large intracellular aggregates termed
neurofibrillary tangles, and their abundance and localization in
the brain correlates with cognitive decline.2,3 As part of the
quality control machinery of the cell, molecular chaperones
such as the highly abundant heat shock protein 70 (Hsp70)
counteract the aggregation of amyloid proteins and target
misfolded species for degradation.4
Over the past few decades, a robust body of literature has
provided evidence for an important role of Hsp70 in the
pathogenesis of AD and other tauopathies, including the
formation of a stable Hsp70−tau complex under conditions of
cell stress,5−7 the regulation of tau degradation,8,9 and the
inhibition of tau aggregation by Hsp70.10−13 Accordingly,
induction or overexpression of Hsp70 in various cell lines leads
to a reduction of insoluble and hyperphosphorylated tau inside
cells and facilitates the association of tau with microtubules and
microtubule polymerization.9,14,15 Further, hippocampal sec-
tions from AD patients show elevated Hsp70 levels as
compared to age-matched controls.13,14 These hippocampal
sections have been found to be either immuno-positive for
Hsp70 or for tau, suggesting that the presence of Hsp70 leads
to a local reduction of insoluble tau.14 These findings illustrate
the capacity of Hsp70 to prevent tau aggregation and target
aberrant tau species for degradation. The inhibitory action on
tau aggregation by Hsp70 was found to be independent of
ATP/ADP and cochaperones.10−12
Currently it is not known which molecular steps of tau
aggregation are inhibited by Hsp70 and which tau species are
targeted by the chaperone. This is partly owed to the difficulty
of studying protein aggregates as they are highly heterogeneous
in nature and can populate rare and transient species such as
small soluble oligomers. Highly sensitive single-molecule
fluorescence methods have previously been employed to
overcome these limitations and to study amyloidogenic
proteins and their interactions at the single aggregate
level.16−24 This has recently allowed an in-depth character-
ization of the oligomerization and fibrillization kinetics of K18
tau (a short tau construct containing the four aggregation prone
repeat regions) and its pathological mutants P301L tau and
ΔK280 tau.25 Particularly the deletion mutant ΔK280 tau was
shown to have a pronounced oligomerization phase, during
which early oligomeric species are highly populated before the
onset of fibrillization. Because of the well-defined aggregation
kinetics of this tau variant and the presence of two Hsp70
binding sites10 within K18 tau, we chose this construct to study
how Hsp70 interacts with the different species formed during
the aggregation of tau. We found that Hsp70 blocks the early
stages of tau aggregation by suppressing the formation of small
tau nuclei. Once tau fibrils are formed, they are sequestered
with low nanomolar affinity (∼20 nM) into a protective
complex by Hsp70, neutralizing the ability of tau to propagate
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by seeded aggregation. Finally, we also demonstrate that Hsp70
reduces the toxic properties of soluble tau oligomers towards
lipid membranes. Taken together, our results show how the
chaperone Hsp70 counteracts the formation, propagation, and
toxicity of tau aggregates.
■ RESULTS AND DISCUSSION
Hsp70 Is a Substoichiometric Inhibitor of Tau
Aggregation. To confirm the inhibitory effect of Hsp70 on
tau aggregation, the fibrillization of K18 ΔK280 tau was
monitored in the absence and presence of Hsp70 using the
reporter dye Thioflavin-T (ThT). ThT is a benzothiazole dye
that exhibits enhanced fluorescence upon binding to beta-sheet
rich amyloid fibrils. As expected, Hsp70 inhibited the
aggregation of tau in a dose-dependent fashion when added
to the aggregation mixture prior to the induction of aggregation
(Figure 1a). To corroborate these findings, a sedimentation
assay was used to measure the relative levels of insoluble K18
ΔK280 tau formed at increasing Hsp70 concentrations. In the
absence of Hsp70, over 80% of the protein was found in the
pellet after 24 h of aggregation. With increasing concentration
of Hsp70, the relative amount of tau in the insoluble tau
fractions decreased, and the majority of tau was detected in the
supernatant (Figure 1b and c).
We note here a discrepancy between the sedimentation assay
and the ThT assay, with the latter showing similar fluorescence
values after 1 day of aggregation for all four conditions.
Therefore, we analyzed the composition of samples after 24 h
by total internal reflection fluorescence (TIRF) microscopy and
transmission electron microscopy (TEM). By using the dye
pentameric formyl thiophene acetic acid (pFTAA), which binds
to beta-sheet rich aggregates similar to the dye ThT, we can
readily detect single fibrils and mature oligomers by TIRF
microscopy.26,27
As evident from the TIRF images and electron micrographs,
tau aggregates were smaller when aggregated with increasing
Hsp70 concentrations, although the majority of aggregates still
appeared to have high beta-sheet content, as evident by pFTAA
staining (see Figure 1d). The majority of these small pFTAA-
active aggregates remained in the supernatant during
centrifugation at 16 000g, explaining the discrepancy between
the recorded ThT-kinetics and the pelleting assay (see Figure
S1). At the highest Hsp70 concentration (1:1 tau/Hsp70),
small oligomeric species were observed by TEM with around
25 nm diameter. These species were still pFTAA-active but
weaker, presumably due to their smaller size (see Figure 1d).
The observation that tau aggregates appear smaller in the
presence of Hsp70 indicates that the chaperone inhibits the
Figure 1. Hsp70 inhibits tau aggregation in a substoichiometric manner. (a) The extent of heparin induced fibrillization of K18 ΔK280 tau (10 μM),
monitored by Thioflavin-T (ThT) fluorescence over the course of the aggregation reaction.N = 3, error bars are s. e. m. (b) Sedimentation assay:
soluble and insoluble K18 ΔK280 tau formed after 24 h at different concentrations of Hsp70. Representative SDS-PAGE analysis, coomassie
staining. N = 3. (c) Relative protein levels in supernatant and pellet by densitometry of SDS-PAGE bands. N = 3, error bars are s. e. m. (d) The
aggregates obtained at the end of the aggregation reactions visualized on a TIRF microscope (pFTAA staining) and by TEM. Representative images
(N = 3). Scale bars: TIRFM 10 μm, TEM 500 nm.
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Figure 2. Hsp70 inhibits tau elongation. (a) Seeded aggregation of K18 ΔK280 tau in the presence of Hsp70. The increase of relative aggregate mass
upon the addition of free monomers (10 μM) to existing seeds (10 μM) was measured over time by ThT fluorescence and normalized. Black line,
tau only; gray line, + 0.5 μMHsp70 (1:20 Hsp70/tau); red line, + 2 μMHsp70 (1:5 Hsp70/tau); blue line, + 10 μMHsp70 (1:1 Hsp70/tau). N = 3,
error bars were omitted for the sake of clarity. Inset: Representative linear fits of the initial aggregation rate to derive the elongation rate of seeds as a
function of Hsp70 concentration. (b) Relative elongation rates (k+) of tau seeds as a function of Hsp70 concentration. Error bars: st. dev. of
experimental repeats. Statistical test: One-way ANOVA; **p ≤ 0.01, ****p ≤ 0.0001.
Figure 3. smFRET shows a reduced number of nuclei in the presence of Hsp70. (a) Typical smFRET spectrum obtained from dual-labeled protein
aggregates on a confocal microscope. Single aggregates passing through the confocal volume gave rise to single FRET events which were quantified
with regard to frequency, intensity, and FRET efficiency. (b) Evolution of K18 ΔK280 tau oligomers as a function of aggregation time. N = 3, error
bars are s. e. m. (c) Apparent sizes of oligomers formed in the absence and presence of Hsp70 after 45 min of aggregation. Sizing reveals a strong
decrease in the population of small nuclei formed in the first hour of aggregation. (d) FRET efficiencies of oligomers in the absence and presence of
Hsp70 after 45 min of aggregation. Black, tau only; gray, 1:20 Hsp70/tau; red, 1:5 Hsp70/tau; blue, 1:1 Hsp70/tau.
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elongation of tau aggregates. Therefore, we next set out to test
this directly using kinetic measurements of elongation.
Hsp70 Inhibits Tau Elongation. To test whether Hsp70
inhibits the elongation of K18 ΔK280 tau fibrils, a seeding assay
was performed using a high concentration of tau seeds. Under
these conditions, the initial aggregation kinetics are determined
purely by the elongation of existing seeds, and thus the relative
elongation rates k+ for different samples can be extracted from
fits of the initial aggregation rates28,29 (see Supporting
Information). Here, tau seeds were prepared from a fibrillar
tau sample, and these were used to seed monomeric tau in the
presence of varying Hsp70 concentrations. The increase of fibril
mass upon fibril elongation was monitored by ThT
fluorescence. Indeed, the aggregation kinetics of tau were
markedly slower in the presence of Hsp70 (Figure 2a). The
relative elongation rate constants (k+) of tau seeds were
Figure 4. Hsp70 affinity to K18 ΔK280 tau aggregates. (a) The binding of Hsp70-AF405 to different tau species was tested by TIRF microscopy.
Representative images are shown (N = 3). Top panel: monomeric tau-AF488 incubated with Hsp70-AF405 under nonaggregating conditions.
Middle panel: tau oligomers (tau-AF488/AF647 coaggregates), aggregated in the presence of Hsp70-AF405. Bottom panel: tau fibrils (pFTAA
stain), incubated with 1.98 μM unlabeled Hsp70 and 0.02 μM Hsp70-AF405. Arrows: colocalization of tau species with Hsp70. Scale bar 10 μm,
insets 2 μm. (b) Schematic of binding assays performed: tau-AF488 aggregates were kept at a constant concentration, and increasing amounts of
Hsp70-AF647 were added until binding saturation was reached. The association between tau-AF488 and Hsp70-AF647 was measured by smFRET
(AF488, donor; AF647, acceptor). (c) Saturation binding curves of Hsp70-AF647 to tau-AF488 aggregates. N = 3, error bars are st. dev. Lines: fits.
(d) Dissociation constants extracted from fits shown in c. Error bars are st. dev.
ACS Chemical Biology Articles
DOI: 10.1021/acschembio.7b01039
ACS Chem. Biol. 2018, 13, 636−646
639
derived from linear fits of the initial aggregation kinetics (see
Figure 2a inset). Plotting these constants as a function of
Hsp70 concentration revealed a dose-dependent decrease of k+
(Figure 2b), corroborating an inhibition of tau aggregate
elongation by Hsp70.
smFRET Shows Inhibition of Tau Nucleation by
Hsp70. Next, we set out to test the effect of Hsp70 on the
early stages of tau aggregation, specifically the formation of
small oligomeric species. For this purpose, we employed a
single-molecule Foerster Resonance Energy Transfer
(smFRET) assay, which is able to detect even the smallest
protein aggregates such as dimers or trimers in an excess of
monomers.21 For this assay, a K18 ΔK280 tau sample was
separated into two aliquots and labeled with two different
fluorophores, a FRET donor (Alexa Fluor 488) and a FRET
acceptor (Alexa Fluor 647). These monomeric versions tau-
AF488 and tau-AF647 were then combined at equal amounts
and coaggregated. In order to monitor the formation of
oligomers, the mixture was diluted to picomolar concentration
and analyzed on a dual-color confocal microscope. Single dual-
labeled aggregates moving through the confocal volume one-
by-one give rise to single FRET events. These can readily be
counted and analyzed with regard to their approximate size and
structure of the aggregate based on their intensity and FRET
efficiency respectively (Figure 3a). This assay was conducted in
the absence and presence of increasing Hsp70 concentrations
to assess the effect of the chaperone on the nucleation and
aggregation of tau.
When K18 ΔK280 tau (5 μM tau-AF488 and 5 μM tau-
AF647) was aggregated in the absence of Hsp70, the protein
rapidly nucleated into a population of oligomers after the
addition of heparin (Figure 3b, black dots). The maximum
number of oligomers was observed after less than 1 h, followed
by a steady decline showing the transient nature of these
oligomers. Strikingly, in the presence of Hsp70, the number of
early oligomers was strongly reduced in a dose-dependent
manner with a 1:5 substoichiometric concentration of Hsp70
leading to a reduction of early oligomeric species by
approximately 50% (Figure 3b, colored dots). This was
particularly evident for small oligomeric species (apparent
size <10mer), which were depleted at the early time points (0−
2 h) (see Figure 3c).
This marked reduction of early oligomeric species in the
presence of the chaperone strongly suggests that primary
nucleation of K18 ΔK280 tau is inhibited by Hsp70. Notably,
besides the suppression of nucleation, our smFRET data also
showed a stabilization of a fraction of early tau oligomers in the
presence of Hsp70 (see Figure 3b, 24 h).
The FRET efficiencies observed for tau oligomers did not
change in the presence of the chaperone, indicating that no
structural change is induced by Hsp70 (Figure 3d).
Affinity of Hsp70 for Different Tau Aggregates. The
data presented above suggest that Hsp70 binds and stabilizes
different K18 ΔK280 tau aggregates such as oligomers and
fibrils. In order to characterize this property in more detail, e.g.,
the binding stoichiometry and affinity, Hsp70 was labeled with
Alexa Fluor 405 (AF405). Then, colocalization studies with
different tau species were performed on a TIRF microscope.
First, the binding of Hsp70-AF405 to labeled tau oligomers was
assessed (1:5 Hsp70/tau stoichiometry). For TIRF imaging,
the oligomeric sample was diluted and adsorbed onto a cover
slide, allowing the visualization of individual dual-labeled
oligomers. Hsp70-AF405 fluorescence also concentrated
around these oligomers, despite incubating the sample at the
exceedingly low protein concentrations needed for single-
molecule imaging (picomolar). This demonstrates the high
kinetic stability of the Hsp70-tau oligomer complex (Figure 4a,
middle panel, arrows). By contrast, the level of colocalization of
Hsp70 incubated with tau monomers was negligible under
these conditions, suggesting rapid complex dissociation (see
Figure 4a, top panel, arrows). Finally, binding of Hsp70 to
mature tau fibrils was assessed. Again, the majority of fibrillar
tau aggregates colocalized with Hsp70, suggesting that Hsp70
also forms a stable complex with tau fibrils (see Figure 4a
bottom panel, arrows).
In order to test the affinity of Hsp70 to different K18 ΔK280
tau aggregates in a more quantitative manner, saturation
binding assays were performed under pseudo-equilibrium
conditions using our smFRET assay (see Supporting
Information for more details). This time, K18 ΔK280 tau-
AF488 was used as a FRET donor and Hsp70 labeled with
AF647 as a FRET acceptor (see Figure 4b). First, increasing
amounts of Hsp70-AF647 were added to tau-AF488 oligomers
and the association of the two proteins was measured for each
concentration. Notably, the single-molecule resolution of our
approach allowed us to assess the binding affinities of Hsp70 to
tau oligomers of different sizes. The size of an aggregate was
estimated based on the fluorescence intensity emitted by the
complex.21 Importantly, this approach is an approximation
which is limited by several factors such as fluorescence
quenching and the nonhomogenous illumination intensity of
the confocal volume. To take this into account, the oligomer
sizes shown here are given as apparent oligomer sizes. The
saturation binding curves and respective dissociation constants
(Kd) obtained for oligomers of different sizes are shown in
Figure 4c,d. These show that the affinity of Hsp70 increases as
a function of oligomer size with an apparent Kd around 170 nM
for large oligomers (10-mers and higher).
Finally, the same binding assay was performed with a fibrillar
tau sample to assess whether the binding affinity to fibrils
follows this trend or is less tight as previously reported.12 The
binding curve obtained for tau fibrils was markedly shifted
toward lower Hsp70 concentrations, and the resulting Kd value
obtained for the binding of Hsp70 to fibrillar tau (19 ± 5 nM)
was an order of magnitude lower than the one obtained for
large oligomers (Figure 4c,d). These results demonstrate that
the apparent binding affinity of Hsp70 to K18 ΔK280 tau
aggregates increases as a function of aggregate size.
Stoichiometry of Hsp70-Binding to Tau Aggregates.
Next, we studied the binding stoichiometry of Hsp70 to tau
oligomers based on our single-molecule data. First, we analyzed
the apparent number of Hsp70 molecules bound to each tau
oligomer from our TIRF images. This revealed a linear
correlation between the size of the tau oligomer and the
number of Hsp70 molecules bound (see Figure S3a). At the
concentrations used for our colocalization study, i.e., a 1:5
Hsp70/tau ratio, the average binding stoichiometry was one
Hsp70 molecule per two tau monomers in an oligomer (see
Figure S3b). To assess how this ratio changes as a function of
Hsp70 concentration, we examined the FRET efficiencies
obtained during the saturation binding smFRET experiment. If
one assumes that the orientation of acceptor molecules to
donor molecules (binding mode of Hsp70 molecules to tau
aggregates) does not change as a function of Hsp70
concentration, the FRET efficiency measured for a tau-Hsp70
complex effectively reports on the number of acceptors (Hsp70
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molecules) bound to the donor (tau; see schematic
representation in Figure S3c). Indeed, the FRET efficiencies
of Hsp70-tau complexes increased from around 0.15 at 10 nM
Hsp70 to 0.65 at 1000 nM Hsp70, indicating that tau
aggregates became increasingly decorated by Hsp70 molecules.
At high acceptor concentrations, the FRET efficiency dropped,
potentially due to nonspecific binding or fluorescence
quenching. Notably, the FRET efficiencies of Hsp70-oligomer
and Hsp70-fibril comlexes did not differ within error, indicating
a similar mode of binding and surface density of Hsp70s to
these different tau species (see Figure S3d).
Hsp70 Prevents Tau Oligomer Toxicity. Tau oligomers
are known to impair the integrity of artificial lipid bilayers.30
The high affinity binding of Hsp70 to K18 ΔK280 tau
oligomers found here could serve as a mechanism to counteract
such harmful interactions with membranes. In order to test this
hypothesis, a single-vesicle permeabilization assay was con-
ducted which allows us to study the ability of aggregates to
permeabilize membranes.31 For this assay, lipid vesicles were
loaded with Cal-520, a dye exhibiting increased fluorescence
upon binding to Ca2+ ions. These vesicles were then
immobilized onto a glass surface and incubated with the
Ca2+-containing buffer L-15. Agents which are able to
permeabilize the membrane of vesicles cause an influx of
Ca2+ ions into the vesicles, leading to an increase in
fluorescence intensity in those vesicles which can readily be
detected on a TIRF microscope (see Figure 5a for a schematic).
When vesicles were treated with 10 nM K18 ΔK280 tau
oligomers, a strong influx of Ca2+ ions into the vesicles was
observed (75% influx compared to the positive control
ionomycin; Figure 5b,c). This finding confirms that tau
oligomers are able to permeabilize lipid membranes as
previously observed.30 At the same concentration, monomeric
tau showed little effect on the vesicles (<20% influx). When tau
was oligomerized in the presence of Hsp70, the previously
observed leakage of Ca2+ into the vesicles by tau oligomers was
strongly reduced to less than 35% Ca2+ influx, corresponding to
about 50% of the initial oligomer response (see Figure 5c). This
was also the case when Hsp70 was added to preformed tau
oligomers just before the measurement (see Supporting Figure
S4). These data show that Hsp70 neutralizes the ability of K18
ΔK280 tau oligomers to perturb lipid bilayers and suggest that
tau toxicity could potentially be mitigated by acute upregulation
or induction of Hsp70.
Summary: Mechanism of Aggregation Inhibition by
Hsp70. In the past few decades, it has become clear that Hsp70
is a key regulator of tau aggregation and turnover.32 However,
mechanistic details on how Hsp70 blocks tau aggregation, such
as the microscopic steps inhibited and the preferred target
species of Hsp70, remain unknown. Here, we used highly
sensitive single-molecule methods to study the interaction of
Hsp70 with the different species on the aggregation pathway of
tau. Using the well-studied tetrapeptide repeat tau construct
K18 ΔK280, which contains the core region of mature tau
filaments33,34 and two Hsp70 binding sites,10 we showed that
Hsp70 blocks both the nucleation andmore efficientlythe
elongation of tau by sequestering aggregates efficiently into a
tight complex.
Protective Sequestration of Tau Monomers. In the
nucleation-conversion model of protein aggregation, which was
recently shown to be applicable to K18 tau and the K18 mutant
studied here,25 small oligomeric nuclei are formed during the
early phase of aggregation, a fraction of which will convert to
growth competent species and elongate by monomer addition.
The remaining oligomers are in equilibrium with the
monomers and will therefore dissociate over time. On the
basis of the low affinity of Hsp70 to monomeric tau
(micromolar Kd of Hsp70 to 0N4R tau monomers
7,35), one
would expect a weak inhibition of the nucleation process by
Hsp70 present at micromolar concentrations in our aggregation
reactions. This is consistent with our single-molecule data,
showing an inhibition of nucleation only at the two highest
Hsp70 concentrations tested. Notably, we found that Hsp70
stabilized a fraction of the oligomers present at the early stages
of the aggregation process. We observed no change in FRET
efficiencies of aggregates in the presence of Hsp70, suggesting
that Hsp70 does not induce off-pathway tau species as observed
for Aβ36 and polyglutamine proteins.37 The inhibitory action of
Figure 5. Hsp70 counteracts the ability of K18 ΔK280 tau aggregates to permeabilize lipid vesicles. (a) Schematic of the membrane disruption assay.
Single Cal520 filled vesicles are immobilized onto a glass cover slide. The addition of agents, which are able to disrupt the membrane of the vesicles,
leads to an influx of Ca2+ ions from the buffer into these vesicles. The resulting increase of fluorescence intensity in each vesicle is detected on a
TIRF microscope. (b,c) Hsp70 neutralizes the ability of K18 ΔK280 tau oligomers to impair lipid membranes. To test the effect of tau species
present at different times of the aggregation reactionon membranes, either 10 nM monomeric tau, oligomeric tau, or Hsp70-tau oligomer
complexes were added to the lipid vesicles. Membrane disruption was measured by an increase of fluorescence intensity in each vesicle. Ionomycin
was used as a positive control to normalize the data (100% Ca2+ influx). N = 4, error are s.e.m. (b) Representative images (N = 4). Scale bar 5 μm.
(c) Data from four independent experiments. Statistical test: One-way ANOVA; ****p ≤ 0.0001.
ACS Chemical Biology Articles
DOI: 10.1021/acschembio.7b01039
ACS Chem. Biol. 2018, 13, 636−646
641
Hsp70 on monomeric tau is likely a relevant factor in vivo, as
the intracellular concentrations of both proteins are in the
micromolar range, and thus the association of free cytosolic tau
to Hsp70 is favored. Indeed, the constitutively expressed Hsp70
homologue Hsc70 was shown to rapidly engage tau monomers
after destabilization of microtubules,15 showing the protective
holdase nature of Hsp70 at the monomeric level (see Figure
6a). Notably, we could not observe direct binding of Hsp70 to
tau monomers after diluting the complex to single-molecule
concentrations (i.e., to picomolar protein concentrations),
showing the transient nature of the Hsp70−tau monomer
interaction. This finding is in agreement with a previous study
which showed that the dissociation of tau monomers from the
constitutively expressed variant Hsc70 occurs with an off-rate of
3.5 × 10−3 s−1 (half-life ∼ 3 min).10
Inhibition of Aggregate Growth and Propagation by
Hsp70. As demonstrated here, Hsp70 has a much higher
affinity to aggregated tau species, with nanomolar Kd values for
oligomers and fibrils. Therefore, the chaperone is likely to bind
more tightly to growing aggregates, leading to an efficient
inhibition of aggregate elongation. Consistent with this
hypothesis, the elongation rate of tau seeds decreased
significantly in the presence of Hsp70. Furthermore, increasing
concentrations of Hsp70 in the reaction mixture led to a
shortening of tau species observed after 24 h of aggregation,
whereby at the highest Hsp70 concentration (1:1 tau/Hsp70),
aggregates were found to be very small oligomeric species,
presumably similar in size to initial converted oligomer. A
sequestration of growth competent seeds and the inhibition of
their elongation by Hsp70 has also been observed for α-
synuclein38 and the yeast prion Ure2,39 suggesting that this
process is one of the key mechanisms by which Hsp70
counteracts the propagation of aggregates and could be the
basis for the strong antiaggregant effect of Hsp70 on tau and
other proteins40 (see Figure 6b). In line with this hypothesis,
hippocampal sections from AD patients are either immunor-
eactive for Hsp70 or fibrillar tau, suggesting that seeds can only
grow and propagate in the absence of the chaperone.14 Despite
this evidence for the protective effects of Hsp70, the role of
Hsp70 in the propagation of pathological protein seeds remains
unclear as the chaperone has been described to be able to
amplify aggregates by fragmentation40,41 and aid the
secretion42,43 or uptake of seeds.44,45
Binding mode of Hsp70 to Tau Aggregates. Interest-
ingly, when we tested the binding of Hsp70 to different tau
species by smFRET, we found no difference in FRET
efficiencies for oligomers and fibrils, suggesting a similar
binding mode to these two aggregate species. This indicates
that the affinity of the chaperone increases only as a function of
aggregate size and that structural differences such as beta-sheet
content are less critical for this interaction. On the basis of our
single-molecule data and a previous report showing that
Hsp70s occupy amyloid fibrils all along the fibril axis,41 the
apparent increase of affinity for larger aggregates is likely a
result of an increased surface area on the aggregate which can
be occupied by the chaperone. Since K18 tau lacks the long N-
and C-terminal projection domains, it forms relatively compact
fibrils.46,47 Given the lack of these relatively loose peptide
stretches extending out from the fibril core and the relatively
narrow substrate binding cleft of Hsp70, the tight binding to
these dense filaments is noteworthy. This structural flexibility of
Hsp70 for substrates of different levels of compaction (e.g.,
monomers vs fibrils) shown here is in agreement with a recent
study on the bacterial Hsp70 homologue DnaK showing the
ability of DnaK to bind to unfolded, partially folded, and near-
native substrates.48 The high affinity of Hsp70 for tau
aggregates may lay the basis for an efficient recruitment of
factors initiating the degradation of tau such as the E3-ligase
CHIP, which was shown to be involved in tau turnover.8,9
Hsp70 Counteracts Tau Toxicity by Direct Binding.
While fibrillar tau species have emerged as the key molecular
species for seeding the aggregation of free monomeric tau in
recipient cells,49 soluble oligomers of tau are thought to confer
damage to cells and play an important role in neuro-
degeneration.50−52 Here, we used lipid vesicles to show that
the tight sequestration of small tau oligomers by Hsp70
mitigates their ability to confer damage to membranes. In a cell,
this might serve to protect the cell membrane or membrane-
rich organelles such as mitochondria or the endoplasmatic
reticulum from toxic effects elicited by tau oligomers (Figure
6c). In a similar manner, the ability of tau aggregates to cross
the cell membrane may be inhibited by Hsp70, hampering the
trans-cellular propagation of tau (Figure 6d).
Conclusion. In summary, we showed here that Hsp70
efficiently blocks the aggregation and toxicity of tau by
sequestering tau aggregates with high affinity. This interaction
may lay the basis for a subsequent clearance of harmful and
seeding competent tau species, e.g., by proteasomal degradation
or chaperone mediated autophagy53 or direct disaggregation of
the aggregates by a Hsp70-driven disaggregase system41,54
(Figure 6e).
■ METHODS AND MATERIALS
Chemicals. Alexa Fluor 488 C5 maleimide, Alexa Fluor 647 C2
maleimide, Alexa Fluor 405 NHS ester, and Alexa Fluor 647 NHS
ester were purchased from Molecular Probes. Heparin (low molecular
weight heparin) was obtained from Fisher Scientific UK. Ammonium
Figure 6. Hsp70 holdase function blocks tau aggregation, propagation,
and toxicity. (a) Hsp70 inhibits the primary nucleation of tau by
stabilizing monomeric and small oligomeric tau species. (b) Hsp70
sequesters growth competent seeds with high affinity and inhibits their
elongation by monomer addition. (c) The binding of small oligomers
by Hsp70 neutralizes their toxic properties such as membrane
disruption. (d) Hsp70 may inhibit the spreading of seeds by
sequestering fibrils and inhibiting their release and uptake. (e) The
holdase function of Hsp70 may be the basis for the subsequent
clearance of aberrant tau aggregates, e.g., via the proteasome,
chaperone mediated autophagy (CMA), or direct disaggregation by
Hsp70.
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acetate, thioflavin T (ThT), and dithiothreitol (DTT) were purchased
from Sigma. pFTAA was a kind gift from Therese Klingstedt.
Protein Expression, Purification, and Labeling. The K18
ΔK280 tau construct used in this work contains a deletion of lysine
280, and both natural cysteine residues were mutated to alanine. It
contains a cysteine mutation at position 260 used for the covalent
attachment of the dyes as previously described.25 The protein was
kindly supplied by Professor St. George-Hyslop and labeled using
Alexa Fluor 488 C5 or 647 C2 maleimide according to established
protocols.
The expression and purification of Hsp70 was performed as
previously described.55 To label Hsp70, the protein was reacted with
Alexa Fluor 405 NHS ester or Alexa Fluor 647 NHS ester according to
established protocols. The labeling efficiency was found to be 1.5
dyes/protein for Hsp70-AF405 by measuring the UV absorbance at
401 nm (εAF405 = 34 000 M
−1 cm−1) and 1.3 dyes/protein for Hsp70-
AF650 by measuring the UV absorbance at 650 nm (εAF650 = 250 000
M−1 cm−1) and the protein concentration determined by BCA assay.
Tau Aggregations and Preparation of Different Tau Species.
All aggregation reactions were performed using 10 μM K18 ΔK280
tau (unlabeled aggregates) or 5 μM ΔK280 tau-AF488 + 5 μM ΔK280
tau-AF647 (dual-labeled aggregates) in 0.05 M ammonium acetate at
pH 7 containing 1 mM DTT. To start the aggregation, 0.01 mg mL−1
of heparin was added to the samples (1:4 heparin/tau ratio). Samples
were incubated at 37 °C without agitation for the indicated amounts of
time. To obtain oligomeric tau, samples were incubated for 45 min and
then transferred to an ice bath. The fraction of oligomers at this stage
of the aggregation is around 10% as estimated by smFRET; i.e., the
oligomer concentration is ∼1 μM (in monomer starting concen-
tration). To obtain fibrillar tau, samples were incubated for 24 h.
Under these conditions, the sample is predominantly fibrillar (≈90%)
with negligible oligomer concentrations (see Figure 3b black dots, and
ref 25).
Monitoring Fibril Formation by Thioflavin-T Fluorescence.
Hsp70 (0 μM, 0.5 μM, 2 μM or 10 μM) was added to K18 ΔK280 tau
(10 μM) in a microwell plate (Corning 96-well half area clear bottom),
and 10 μM ThT was added. Fibrillation was monitored by excitation at
440 nm and collecting fluorescence at 480 nm using a BMG FLUOstar
OPTIMA plate reader.
Tau and Hsp70 Pelleting Assays. Hsp70 (0 μM, 0.5 μM, 2 μM
or 10 μM) was added to K18 ΔK280 tau (10 μM) in a 200 μL PCR
tube at 4 °C. The aggregation was started by heparin addition and
continued for the indicated amounts of time at 37° C. To analyze the
amount of soluble and insoluble protein after given periods of time,
each mixture was centrifuged at 16 000g for 20 min. Supernatant and
pellet fractions were then subjected to SDS-PAGE using 4−12% Bis-
Tris gels (Bolt, Thermo Fisher Scientific) and protein bands stained
with colloidal coomassie (BioRad). To quantify soluble and insoluble
protein, densitometry was performed on the protein bands, and
protein levels were normalized to a nonaggregated control containing
10 μM ΔK280 tau only.
Determining Elongation Rates of Tau Seeds in the Presence
of Hsp70. Tau was fibrillated as described above. After 24 h, the fibrils
were separated from soluble tau species by centrifugation at 16 000g
for 15 min. The fibrils were then resuspended in a tenth of the original
volume in 0.05 M ammonium acetate at pH 7 containing 1 mM DTT,
vortexed for 10 s, and sonicated for 15 s in a water bath. Then, 10 μM
seeds; 10 μM K18 ΔK280 tau; and 0 μM, 0.5 μM, 2 μM, or 10 μM
Hsp70 were combined in an aggregation buffer containing 10 μM ThT
and heparin in a microwell plate (Corning 96-well half area clear
bottom). ThT kinetics were monitored in a plate reader as described
above. To extract relative elongation rates from the recorded
aggregation kinetics, the raw data were fitted as described in the
Supporting Information.
smFRET Instrumentation and Data Acquisition. The confocal
FRET instrument and the data acquisition have previously been
described in detail.17,25
smFRET Analysis of Tau Oligomerization. In order to study the
oligomerization of tau, equimolar amounts of monomeric AF488-
labeled ΔK280 tau and AF647-labeled ΔK280 tau were combined at a
concentration of 10 μM in a 200 μL PCR tube at 4 °C. To test the
effect of Hsp70 on the aggregation of tau, indicated amounts of the
chaperone were added prior to the initiation of aggregation. To start
the aggregation, heparin was added to the aggregation mixture and the
sample incubated at 37° C. The first time point (t0) was measured
before the addition of heparin. For smFRET analysis, samples were
diluted into 0.05 M ammonium acetate at pH 7 to a final protein
concentration of 200 pM, and the sample was flowed through the
channel of a microfluidic device mounted on a confocal setup as
described previously.20 The data were analyzed as described
previously,17,25 and a summary can be found in the Supporting
Information.
Testing the Binding of Hsp70 to Tau by TIRF Microscopy. To
assess direct binding of Hsp70 to monomeric tau, 10 μM ΔK280 tau-
AF488 was mixed with 2 μM Hsp70-AF405 in a 200 μL PCR tube,
and the sample was incubated on ice for 10 min. To assess the direct
binding of Hsp70 to oligomeric tau, dual-labeled tau oligomers were
produced as described above in the presence of 2 μM Hsp70-AF405 in
a 200 μL PCR tube. Then, samples were diluted into 0.05 M
ammonium acetate at pH 7 to a tau concentration of 50−200 pM and
adsorbed onto a glass cover slide for 15 min and imaged on a TIRF
microscope using the appropriate illumination sources and emission
filters.
To test the binding of Hsp70 to fibrillar tau, unlabeled ΔK280 tau
was fibrillated as described above for 24 h. This fibrillar sample was
then incubated with 1.98 μM unlabeled Hsp70 and 0.02 μM Hsp70-
AF405 for 10 min on ice. Finally, the sample was diluted to a tau
concentration of 25 nM into 0.05 M ammonium acetate at pH 7
containing 30 nM of the fibrillar stain pFTAA, adsorbed onto a glass
cover slide for 15 min, and visualized by TIRF microscopy using the
appropriate illumination sources and emission filters.
To control for bleed-through and cross-excitation of fluorophores,
identical samples were prepared where only one of the interaction
partners was fluorescently labeled. Both bleed-through and cross-
excitation were negligible.
The TIRF microscope and the binding stoichiometry analysis are
described in the Supporting Information.
Measuring Binding Affinities of Hsp70 to Tau by smFRET.
Testing Association and Disassociation Kinetics. See the Supporting
Information.
Saturating Binding Curves. Tau oligomers or fibrils were prepared
as described above. Notably, to remove any nonfibrillar material, the
fibrils were separated from soluble tau species by centrifugation at
16 000g for 15 min. The fibrils were then resuspended in 45 μL of 0.05
M ammonium acetate at pH 7 containing 1 mM DTT, vortexed for 10
s, and sonicated for 15 s in a water bath.
To perform binding saturation experiments, 100 nM oligomers or
1200 nM fibrils (initial monomer concentration) were mixed with
increasing Hsp70 concentrations from 0.5 nM to 10 μM and incubated
for 5 min on ice. Then, the sample was diluted to a 200 pM tau
concentration, and the association was determined by smFRET (data
analysis described in the Supporting Information).
Lipid Vesicles Permeabilization Assay. Tau samples were
oligomerized as described above. The purification of lipid vesicles,
their attachment onto glass coverslides, and the TIRF microscope used
for imaging are described in detail in ref 31. To test the effect of tau on
the lipid vesicles, 50 μL of either (i) 10 nM tau monomers, (ii) 10 nM
tau oligomers, or (iii) 10 nM tau oligomers plus Hsp70 (2 nM) were
added onto the coverslip and incubated for 10 min. Importantly, glass
coverslips were not moved during the addition of samples. Then
images were acquired. Next, 10 μL of a solution containing 1 mg mL−1
of ionomycin (Cambridge Bioscience Ltd.) was added and incubated
for 5 min, and subsequently images of Ca2+-saturated single vesicles in
the same fields of view were acquired. Vesicles were visualized by
TIRF microscopy using the appropriate illumination sources and
emission filters. The recorded images were analyzed using ImageJ56 to
determine the fluorescence intensity of each spot under the three
different conditions, namely, background (Fbackground), in the presence
of a sample (Fsample), and after the addition of ionomycin (FIonomycin).
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The relative influx of Ca2+ ions due to the presence of the respective
tau sample was then determined using the following equation:
− =
−
−
+
F F
F F
Ca influx2
sample background
Ionomycin blank (1)
Statistics. Statistical analysis was performed with OriginPro 2016.
One-way ANOVA followed by a post hoc Tukey test was used.
Differences were considered to be significantly different if p < 0.05.
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